Hepatitis C, Chronic Clinical Trial
Official title:
Educate, Test and Treat Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages
Background: The global response to the HCV infection epidemic has been transformed by the
availability of low-cost curative short course direct acting antiviral (DAA) therapy. Egypt
has one of the highest burdens of HCV infection worldwide, and a large treatment programme,
but reaching rural communities represents a major challenge. We report the feasibility and
effectiveness of a comprehensive community-based HCV prevention, testing and treatment model
in 73 villages across Egypt, with the goal to eliminate infection from all adult villagers.
Methods: An HCV "educate, test and treat" programme was implemented in 73 villages across 7
governorates in Egypt between 06/2015 and 06/2018. The programme model comprised community
mobilization facilitated by a network of village promoters to support the education, test and
treat campaign as well as fund raising in the local community; a comprehensive testing,
linkage to care and treatment of all eligible villagers aged 12 to 80 years using HCV
antibody and HBsAg rapid diagnostic tests (RDTs), HCV RNA confirmation of positive cases,
staging of liver disease using transient elastography (FibroScan), treatment with 12 or 24
weeks of a direct acting antiviral (DAA) regimen according to national standard of HCV care,
and an assessment of cure at 12 weeks after completion of treatment (SVR12); and an education
campaign to raise awareness and disseminate messages about safer practices to reduce
transmission through public events, promotional materials and house-to-house visits. Key
outcomes assessed in each village were: uptake of serological HCV and HBV testing, linkage to
assessment and HCV viral load confirmation, uptake of treatment, and SVR12.
Background: The global response to the HCV infection epidemic has been transformed by the
availability of low-cost curative short course direct acting antiviral (DAA) therapy. Egypt
has one of the highest burdens of HCV infection worldwide, and a large treatment programme,
but reaching rural communities represents a major challenge. We report the feasibility and
effectiveness of a comprehensive community-based HCV prevention, testing and treatment model
in 73 villages across Egypt, with the goal to eliminate infection from all adult villagers.
Methods: An HCV "educate, test and treat" programme was implemented in 73 villages across 7
governorates in Egypt between 06/2015 and 06/2018. The programme model comprised community
mobilization facilitated by a network of village promoters to support the education, test and
treat campaign as well as fund raising in the local community; a comprehensive testing,
linkage to care and treatment of all eligible villagers aged 12 to 80 years using HCV
antibody and HBsAg rapid diagnostic tests (RDTs), HCV RNA confirmation of positive cases,
staging of liver disease using transient elastography (FibroScan), treatment with 12 or 24
weeks of a direct acting antiviral (DAA) regimen according to national standard of HCV care,
and an assessment of cure at 12 weeks after completion of treatment (SVR12); and an education
campaign to raise awareness and disseminate messages about safer practices to reduce
transmission through public events, promotional materials and house-to-house visits. Key
outcomes assessed in each village were: uptake of serological HCV and HBV testing, linkage to
assessment and HCV viral load confirmation, uptake of treatment, and SVR12.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03740906 -
Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting
|
||
Terminated |
NCT02465203 -
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
|
Phase 3 | |
Completed |
NCT02262728 -
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
|
Phase 2 | |
Completed |
NCT01429792 -
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
|
Phase 4 | |
Completed |
NCT02541409 -
Directly Observed Therapy for HCV in Chennai, India
|
Phase 2 | |
Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
Withdrawn |
NCT01608737 -
A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection
|
Phase 3 | |
Completed |
NCT01447446 -
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
|
N/A | |
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Completed |
NCT01399619 -
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
|
Phase 3 | |
Completed |
NCT01435044 -
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
|
Phase 2 | |
Completed |
NCT01435226 -
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
|
Phase 2 | |
Terminated |
NCT01168856 -
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
|
N/A | |
Completed |
NCT00725751 -
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
|
N/A | |
Completed |
NCT00793793 -
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
|
Phase 1 | |
Completed |
NCT00377182 -
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
|
Phase 2 | |
Completed |
NCT00375661 -
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
|
Phase 4 | |
Completed |
NCT00704717 -
Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)
|
N/A | |
Completed |
NCT00217139 -
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
|
Phase 2 |